Current and Novel Approach for Influenza vaccines

The first and foremost efforts to develop influenza vaccines were initiated soon after influenza A and B viruses were identified as the etiologic agents of clinical influenza. The United States in 1945 has approved the first commercial vaccines using whole-inactivated influenza virus for use. The flu vaccine is an annual vaccination using a vaccine to protect against the highly variable influenza virus that is specific for a given year. Risk management and effectiveness of vaccines are important for public health.

  • Genetic and evolution of virus and host
  • Risk management and effectiveness of vaccines
  • Targeting strategies for influenza vaccines
  • Clinical trials of influenza based vaccines

Related Conference of Current and Novel Approach for Influenza vaccines

January 27-28, 2020

3rd Global Experts Meeting on Infectious Diseases

Bangkok, Thailand
February 10-11, 2020

2nd Global Experts Meet on STD-AIDS and Infectious Diseases

Sydney, Australia
February 24-25, 2020

13thWorld Congress on Virology and Infectious Diseases

Tokyo, Japan
February 24-25, 2020

7th International Congress on Infectious Diseases

Berlin, Germany
March 11-12, 2020

8th International Conference on HIV AIDS STD & STIs

Barcelona, Spain
April 27-28, 2020

7th Global Congress on Rare Diseases & Orphan Drug

Istanbul, Turkey
July 22-23, 2020

10th World Congress on Rare Diseases and Orphan Drugs

Barcelona, Spain
August 19-20, 2020

European Summit on HIV, STD and STIs

Milan, Italy
September 28-29, 2020

13th Global Infections Conference

Singapore
October 5-6, 2020

12th Euro-Global Conference on Infectious Diseases

Vienna, Austria
November 25-26, 2020

Intercontinental Conference on Infectious Diseases

Tokyo, Afghanistan

Current and Novel Approach for Influenza vaccines Conference Speakers

Recommended Sessions

Related Journals

Are you interested in